Cost-effectiveness analysis of paclitaxel

被引:3
作者
Eandi, Mario [1 ]
机构
[1] Univ Torino, Ordinario Farmacol Clin, Turin, Italy
关键词
non-small cell lung cancer (NSCLC); paclitaxel/carboplatin; gemcitabine/cisplatin; vinorelbine/cisplatin; cost-effectiveness analysis;
D O I
10.7175/fe.v7i2.680
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its medical and economical burden represents a serious matter in Europe and Usa, due to its high mortality rates and drug costs. Lung cancer is responsible for about 30% of cancer death in men and women; in Europe only about 8 per cent of people with lung cancer survive for 5 years. At present combination chemotherapy based on cisplatin or carboplatin associated with paclitaxel, vinorelbine or gemcitabine is the state of the art for the treatment in patients with stage IIIb or IV NSCLC. Aim of this study was to compare the cost-effectiveness of paclitaxel/carboplatin (PCb), gemcitabine/cisplatin (GC) and vinorelbine/cisplatin (VC) in the perspective of the Italian National Health Service. Therefore we perfomed a semi-Markov decision model mainly based on clinical results from the Italian Lung Cancer Project. The model included differential direct medical costs registered for two years from starting chemotherapy, using tariffs valid for 2005. Benefits was measured by years of life saved (YOLs). The model also allowed to estimate only costs accrued over the period of time, performing a cost-minimisation analysis. According to cost-effectiveness analysis, VC is dominated because it's more costly and less effective than GC. On the contrary, combination chemotherapy with GC is more inexpensive but less effective than paclitaxel/ carboplatin (PCb): in this case we compared the incremental cost-effectiveness ratio (ICER) with a maximum acceptable willingness-to-pay (WTP) value. In the base scenario the ICER of PCb over GC treatment is 52,326 euro/YOLs, which is definitely lower than the maximum acceptable WTP value. Sensitivity analyses confirmed the robustness of the results from cost-effectiveness analysis in the base scenario.
引用
收藏
页码:97 / 117
页数:21
相关论文
共 34 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer [J].
Billingham, LJ ;
Bathers, S ;
Burton, A ;
Bryan, S ;
Cullen, MH .
LUNG CANCER, 2002, 37 (02) :219-225
[3]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[4]  
BUNN PA, 1994, SEMIN ONCOL, V21, P49
[5]   Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated [J].
Chen, YM ;
Perng, RP ;
Lee, YC ;
Shih, JF ;
Lee, CS ;
Tsai, CM ;
Whang-Peng, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :108-115
[6]   Economics of the clinical management of lung cancer in France:: an analysis using a Markov model [J].
Chouaïd, C ;
Molinier, L ;
Combescure, C ;
Daurès, JP ;
Housset, B ;
Vergnenègre, A .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :397-402
[7]   Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review [J].
Clegg, A ;
Scott, DA ;
Hewitson, P ;
Sidhu, M ;
Waugh, N .
THORAX, 2002, 57 (01) :20-28
[8]   Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy Cooperative Oncology Group [J].
Comella, P ;
Frasci, G ;
Panza, N ;
Manzione, L ;
De Cataldis, G ;
Cioffi, R ;
Maiorino, L ;
Micillo, E ;
Lorusso, V ;
Di Rienzo, G ;
Filippelli, G ;
Lamberti, A ;
Natale, M ;
Bilancia, D ;
Nicolella, G ;
Di Nota, A ;
Comella, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1451-1457
[9]   Uncertainty in decision models analyzing cost-effectiveness [J].
Craig, BA ;
Black, MA ;
Sendi, PP .
MEDICAL DECISION MAKING, 2000, 20 (01) :135-136
[10]   Cost-effectiveness analysis in oncology [J].
Earle, CC ;
Coyle, D ;
Evans, WK .
ANNALS OF ONCOLOGY, 1998, 9 (05) :475-482